Business as Usual as China Bribery Scandal Widens
By Shannon Ellis
Friday, August 30, 2013
SHANGHAI – Four multinational pharmaceutical firms have been hit with allegations of bribery in China since the Glaxosmithkline plc scandal first broke almost two months ago. China’s State Administration for Industry & Commerce (SAIC) has announced a three-month probe that will target pharmaceutical and medical device sales.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.